Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.  [electronic resource] 

 -  Ophthalmology  Jun 2006 
 - 992-1001.e6 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1549-4713 
<br/><br/><label>Standard No.: </label>10.1016/j.ophtha.2006.02.027  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Aptamers, Nucleotide--adverse effects<br/>Choroidal Neovascularization--drug therapy<br/>Double-Blind Method<br/>Female<br/>Fluorescein Angiography<br/>Humans<br/>Injections<br/>Intraocular Pressure--drug effects<br/>Macular Degeneration--complications<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--drug effects<br/>Vitreous Body